HIV Clinical Trials
Theratechnologies has started a patient registry for Trogarzo® in Europe.
In addition, an intravenous (IV) push administration of Trogarzo® for the treatment of human immunodeficiency virus type 1 (HIV-1) infection is currently being evaluated by TaiMed Biologics Inc, Theratechnologies’ partner. The study is expected to be completed in the third quarter of 2021.
Theratechnologies and TaiMed are also planning to evaluate an intramuscular (IM) method of administration for Trogarzo®.